CPX-351 (Vyxeos) for tAML / AML-MRC 1L

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-CPX-351` `DRUG-CPX-351`

ID	`REG-CPX351-AML`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ELN-AML-2022` `SRC-LANCET-CPX351-2018` `SRC-NCCN-AML-2025`

Notes

FDA-approved specifically for newly-dx tAML or AML-MRC in older (60-75) patients. Median OS 9.56 vs 5.95 mo for 7+3 (HR 0.69). Bridge to alloHCT in CR1 for fit candidates — combination of better CR rate + alloHCT eligibility drives survival benefit. STUB — pending Co-Lead sign-off.

Used By

Indication

IND-AML-1L-CPX351-SECONDARY - IND-AML-1L-CPX351-SECONDARY